Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Scott A. Armstrong, M.D.,Ph.D.

Co-Author

This page shows the publications co-authored by Scott Armstrong and Andrei Krivtsov.
Connection Strength

7.086
  1. A Menin-MLL Inhibitor Induces Specific Chromatin Changes and Eradicates Disease in Models of MLL-Rearranged Leukemia. Cancer Cell. 2019 12 09; 36(6):660-673.e11.
    View in: PubMed
    Score: 0.900
  2. Mixed-Lineage Leukemia Fusions and Chromatin in Leukemia. Cold Spring Harb Perspect Med. 2017 Nov 01; 7(11).
    View in: PubMed
    Score: 0.778
  3. Cancer. Can one cell influence cancer heterogeneity? Science. 2012 Nov 23; 338(6110):1035-6.
    View in: PubMed
    Score: 0.553
  4. Transformation from committed progenitor to leukemia stem cells. Ann N Y Acad Sci. 2009 Sep; 1176:144-9.
    View in: PubMed
    Score: 0.442
  5. Gene expression profiling of leukemia stem cells. Methods Mol Biol. 2009; 538:231-46.
    View in: PubMed
    Score: 0.422
  6. H3K79 methylation profiles define murine and human MLL-AF4 leukemias. Cancer Cell. 2008 Nov 04; 14(5):355-68.
    View in: PubMed
    Score: 0.417
  7. MLL translocations, histone modifications and leukaemia stem-cell development. Nat Rev Cancer. 2007 Nov; 7(11):823-33.
    View in: PubMed
    Score: 0.389
  8. Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature. 2006 Aug 17; 442(7104):818-22.
    View in: PubMed
    Score: 0.356
  9. Novel inhibitors of the histone methyltransferase DOT1L show potent antileukemic activity in patient-derived xenografts. Blood. 2020 10 22; 136(17):1983-1988.
    View in: PubMed
    Score: 0.239
  10. Therapeutic targeting of preleukemia cells in a mouse model of NPM1 mutant acute myeloid leukemia. Science. 2020 01 31; 367(6477):586-590.
    View in: PubMed
    Score: 0.227
  11. Inhibition of MEK and ATR is effective in a B-cell acute lymphoblastic leukemia model driven by Mll-Af4 and activated Ras. Blood Adv. 2018 10 09; 2(19):2478-2490.
    View in: PubMed
    Score: 0.208
  12. LSD1 inhibition exerts its antileukemic effect by recommissioning PU.1- and C/EBPa-dependent enhancers in AML. Blood. 2018 04 12; 131(15):1730-1742.
    View in: PubMed
    Score: 0.199
  13. Selective Inhibition of HDAC1 and HDAC2 as a Potential Therapeutic Option for B-ALL. Clin Cancer Res. 2015 May 15; 21(10):2348-58.
    View in: PubMed
    Score: 0.161
  14. MLL partial tandem duplication leukemia cells are sensitive to small molecule DOT1L inhibition. Haematologica. 2015 May; 100(5):e190-3.
    View in: PubMed
    Score: 0.160
  15. AF10 regulates progressive H3K79 methylation and HOX gene expression in diverse AML subtypes. Cancer Cell. 2014 Dec 08; 26(6):896-908.
    View in: PubMed
    Score: 0.159
  16. MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. Cancer Cell. 2011 Jul 12; 20(1):66-78.
    View in: PubMed
    Score: 0.126
  17. The Wnt/beta-catenin pathway is required for the development of leukemia stem cells in AML. Science. 2010 Mar 26; 327(5973):1650-3.
    View in: PubMed
    Score: 0.115
  18. HOXA9 is required for survival in human MLL-rearranged acute leukemias. Blood. 2009 Mar 12; 113(11):2375-85.
    View in: PubMed
    Score: 0.105
  19. MLL-AF9 and FLT3 cooperation in acute myelogenous leukemia: development of a model for rapid therapeutic assessment. Leukemia. 2008 Jan; 22(1):66-77.
    View in: PubMed
    Score: 0.096
  20. A dominant-negative effect drives selection of TP53 missense mutations in myeloid malignancies. Science. 2019 08 09; 365(6453):599-604.
    View in: PubMed
    Score: 0.055
  21. IKZF2 Drives Leukemia Stem Cell Self-Renewal and Inhibits Myeloid Differentiation. Cell Stem Cell. 2019 01 03; 24(1):153-165.e7.
    View in: PubMed
    Score: 0.052
  22. The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia. Blood. 2018 06 14; 131(24):2661-2669.
    View in: PubMed
    Score: 0.050
  23. MEF2C Phosphorylation Is Required for Chemotherapy Resistance in Acute Myeloid Leukemia. Cancer Discov. 2018 04; 8(4):478-497.
    View in: PubMed
    Score: 0.050
  24. Peptidomimetic blockade of MYB in acute myeloid leukemia. Nat Commun. 2018 01 09; 9(1):110.
    View in: PubMed
    Score: 0.049
  25. SETD2 alterations impair DNA damage recognition and lead to resistance to chemotherapy in leukemia. Blood. 2017 12 14; 130(24):2631-2641.
    View in: PubMed
    Score: 0.048
  26. A UTX-MLL4-p300 Transcriptional Regulatory Network Coordinately Shapes Active Enhancer Landscapes for Eliciting Transcription. Mol Cell. 2017 Jul 20; 67(2):308-321.e6.
    View in: PubMed
    Score: 0.048
  27. Functional screen of MSI2 interactors identifies an essential role for SYNCRIP in myeloid leukemia stem cells. Nat Genet. 2017 Jun; 49(6):866-875.
    View in: PubMed
    Score: 0.047
  28. DNMT3A mutations promote anthracycline resistance in acute myeloid leukemia via impaired nucleosome remodeling. Nat Med. 2016 12; 22(12):1488-1495.
    View in: PubMed
    Score: 0.045
  29. Reply to "Uveal melanoma cells are resistant to EZH2 inhibition regardless of BAP1 status". Nat Med. 2016 06 07; 22(6):578-9.
    View in: PubMed
    Score: 0.044
  30. Erratum: Modulation of splicing catalysis for therapeutic targeting of leukemia with mutations in genes encoding spliceosomal proteins. Nat Med. 2016 06 07; 22(6):692.
    View in: PubMed
    Score: 0.044
  31. Modulation of splicing catalysis for therapeutic targeting of leukemia with mutations in genes encoding spliceosomal proteins. Nat Med. 2016 06; 22(6):672-8.
    View in: PubMed
    Score: 0.044
  32. A chromatin-independent role of Polycomb-like 1 to stabilize p53 and promote cellular quiescence. Genes Dev. 2015 Nov 01; 29(21):2231-43.
    View in: PubMed
    Score: 0.042
  33. Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias. Blood. 2015 Nov 26; 126(22):2479-83.
    View in: PubMed
    Score: 0.042
  34. Loss of BAP1 function leads to EZH2-dependent transformation. Nat Med. 2015 Nov; 21(11):1344-9.
    View in: PubMed
    Score: 0.042
  35. Mediator kinase inhibition further activates super-enhancer-associated genes in AML. Nature. 2015 Oct 08; 526(7572):273-276.
    View in: PubMed
    Score: 0.042
  36. Hematopoietic Differentiation Is Required for Initiation of Acute Myeloid Leukemia. Cell Stem Cell. 2015 Nov 05; 17(5):611-23.
    View in: PubMed
    Score: 0.042
  37. Requirement for CDK6 in MLL-rearranged acute myeloid leukemia. Blood. 2014 Jul 03; 124(1):13-23.
    View in: PubMed
    Score: 0.038
  38. Pathprinting: An integrative approach to understand the functional basis of disease. Genome Med. 2013; 5(7):68.
    View in: PubMed
    Score: 0.036
  39. EVI1 is critical for the pathogenesis of a subset of MLL-AF9-rearranged AMLs. Blood. 2012 Jun 14; 119(24):5838-49.
    View in: PubMed
    Score: 0.033
  40. The Stem Cell Discovery Engine: an integrated repository and analysis system for cancer stem cell comparisons. Nucleic Acids Res. 2012 Jan; 40(Database issue):D984-91.
    View in: PubMed
    Score: 0.032
  41. Crebbp haploinsufficiency in mice alters the bone marrow microenvironment, leading to loss of stem cells and excessive myelopoiesis. Blood. 2011 Jul 07; 118(1):69-79.
    View in: PubMed
    Score: 0.031
  42. MLL-rearranged B lymphoblastic leukemias selectively express the immunoregulatory carbohydrate-binding protein galectin-1. Clin Cancer Res. 2010 Apr 01; 16(7):2122-30.
    View in: PubMed
    Score: 0.029
  43. Mef2C is a lineage-restricted target of Scl/Tal1 and regulates megakaryopoiesis and B-cell homeostasis. Blood. 2009 Apr 09; 113(15):3461-71.
    View in: PubMed
    Score: 0.027
  44. Conditional MLL-CBP targets GMP and models therapy-related myeloproliferative disease. EMBO J. 2005 Jan 26; 24(2):368-81.
    View in: PubMed
    Score: 0.020
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.